The FDA has approved the use of Fasenra (benralizumab) for the treatment of severe asthma in children aged 6 to 11 years, following positive results from the TATE trial. A new 10 mg dose will be available for children who weigh less than 35 kg. Fasenra is administered by subcutaneous injection every 4 weeks for the first 3 doses, then once every 8 weeks. The approval was supported by evidence from the TATE study as well as trials in adult and adolescent populations. AstraZeneca aims to continue evaluating Fasenra’s potential to treat different age groups across disease states.
Source link
Fasenra receives FDA approval for asthma treatment in children aged 6 to 11 years
